Thu, Mar 13, 2025
[Archive]
1- Children's Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Children's Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran;Department of Biostatistics and Epidemiology, School of Health, Golestan University of Medical Sciences, Gorgan, Iran
3- Children's Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,s.a.aghapour@googlemail.com
2- Children's Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran;Department of Biostatistics and Epidemiology, School of Health, Golestan University of Medical Sciences, Gorgan, Iran
3- Children's Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,
Abstract: (313 Views)
Background: On December 8, 2019, cases of pneumonia from an unknown disease were identified in Wuhan, China. Investigations showed that this disease was COVID-19, caused by the SARS-CoV-2 coronavirus. This study aimed to investigate the prevalence of asthma in patients with COVID-19 and its relationship to asthma severity.
Methods: In this cross-sectional study, we obtained patients' data from medical records, including their asthma history, severity, and COVID-19 outcomes (mortality). Logistic regression was used to measure the association between asthma severity and COVID-19 mortality. The collected data were analyzed using SPSS software (version 23).
Results: The study showed that asthma was present in 14.4% of the patients with COVID-19. Regarding asthma severity, 61.9%, 16.4%, and 21.6% of the patients had mild, moderate, and severe asthma, respectively. The overall mortality rate among the patients with COVID-19 was 21.42%. There was a significant association between asthma and COVID-19 mortality (p-value = 0.003). However, asthma severity was not related to COVID-19 mortality (p-value = 0.50).
Conclusion: The lower mortality rate in patients with severe asthma may be attributed to corticosteroid use, which is less common in patients with mild asthma. Inhaled corticosteroids may offer protection against severe COVID-19 in asthma patients and could potentially help treat COVID-19.
Methods: In this cross-sectional study, we obtained patients' data from medical records, including their asthma history, severity, and COVID-19 outcomes (mortality). Logistic regression was used to measure the association between asthma severity and COVID-19 mortality. The collected data were analyzed using SPSS software (version 23).
Results: The study showed that asthma was present in 14.4% of the patients with COVID-19. Regarding asthma severity, 61.9%, 16.4%, and 21.6% of the patients had mild, moderate, and severe asthma, respectively. The overall mortality rate among the patients with COVID-19 was 21.42%. There was a significant association between asthma and COVID-19 mortality (p-value = 0.003). However, asthma severity was not related to COVID-19 mortality (p-value = 0.50).
Conclusion: The lower mortality rate in patients with severe asthma may be attributed to corticosteroid use, which is less common in patients with mild asthma. Inhaled corticosteroids may offer protection against severe COVID-19 in asthma patients and could potentially help treat COVID-19.
Type of Study: Original Article |
Subject:
Health economic
Received: 2024/09/18 | Accepted: 2024/11/23
Received: 2024/09/18 | Accepted: 2024/11/23
References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Betthäuser BA, Bach-Mortensen AM, Engzell P. A systematic review and meta-analysis of the evidence on learning during the COVID-19 pandemic. Nat Hum Behav. 2023;7(3):375-85. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6):e79. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19. N Engl J Med. 2020;383(19):1813-26. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Wagner A, Liberatore F, Schmelzer S, Dratva J. Confident and altruistic-parents' motives to vaccinate their children against COVID-19: a cross-sectional online survey in a Swiss vaccination centre. Swiss Med Wkly. 2022;152(1112):w30156-w. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Marcdante K, Kliegman RM. Nelson essentials of pediatrics e-book: Philadelphia:Elsevier Health Sciences;2014. [View at Publisher] [Google Scholar]
8. Adir Y, Saliba W, Beurnier A, Humbert M. Asthma and COVID-19: an update. Eur Respir Rev. 2021;30(162):210152. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Johnston SL. Asthma and COVID‐19: is asthma a risk factor for severe outcomes? Allergy. 2020;75(7):1543-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Broadhurst R, Peterson R, Wisnivesky JP, Federman A, Zimmer SM, Sharma S, et al. Asthma in COVID-19 hospitalizations: an overestimated risk factor? Ann Am Thorac Soc. 2020;17(12):1645-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Assaf S, Stenberg H, Jesenak M, Tarasevych SP, Hanania NA, Diamant Z. Asthma in the era of COVID-19. Respir Med. 2023;218:107373. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Lovinsky-Desir S, Deshpande DR, De A, Murray L, Stingone JA, Chan A, et al. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol. 2020;146(5):1027-34. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Lee SC, Son KJ, Han CH, Jung JY, Park SC. Impact of comorbid asthma on severity of coronavirus disease (COVID-19). Sci Rep. 2020;10(1):21805. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Shah P, Owens J, Franklin J, Mehta A, Heymann W, Sewell W, et al. Demographics, comorbidities and outcomes in hospitalized Covid-19 patients in rural southwest Georgia. Ann Med. 2020;52(7):354-60. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Almazeedi S, Al-Youha S, Jamal MH, Al-Haddad M, Al-Muhaini A, Al-Ghimlas F, et al. Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait. EClinicalMedicine. 2020;24:100448. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Lieberman-Cribbin W, Rapp J, Alpert N, Tuminello S, Taioli E. The impact of asthma on mortality in patients with COVID-19. Chest. 2020;158(6):2290-1. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763-72. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155-68. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Izquierdo Alonso JL, Almonacid Sanchez C, Gonzalez Y, Del Rio C, Ancochea J, Cárdenas R, et al. The impact of COVID-19 on patients with asthma: A Big Data analysis. Eur Respir J. 2021;57(3):2003142. [View at Publisher] [DOI] [Google Scholar]
21. So M, Kabata H, Takahashi M, Egorova NN, Kuno T. The association of inhaled corticosteroid before admission and survival of patients with COVID-19. J Aerosol Med Pulm Drug Deliv. 2021;34(4):265-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
